10-Q · May 14, 2026
Actuate Therapeutics remains firmly in a pre-revenue stage, reporting no revenue for Q1 2026 once again. The net loss for the quarter was $5.63 million, a slight improvement compared to the $6.32 million loss in Q1…
Earnings analysis · 10-Q
ACTU earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text does not include income statement, balance sheet, cash flow, segment, or quantitative guidance data, so operating trends and EPS performance cannot be assessed. Management reported effective…
Read full summary
The extracted 10-Q text does not include income statement, balance sheet, cash flow, segment, or quantitative guidance data, so operating trends and EPS performance cannot be assessed. Management reported effective disclosure controls as of June 30, 2026 and no material internal-control changes during the quarter. The principal material development is the Nasdaq listing deficiency: the company was below the $50 million MVLS requirement and has until January 11, 2027 to regain compliance.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
-
No material control changes
The company reported no changes in internal control over financial reporting during the three months ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, those controls.
What to watch
-
Nasdaq MVLS deficiency
The company is not currently compliant with Nasdaq Global Market's $50 million minimum market value of listed securities requirement. Nasdaq notified the company on July 15, 2026 that it had failed the requirement for the 30-business-day period ended July 14, 2026.
-
Potential Nasdaq delisting
The company has until January 11, 2027 to restore compliance by maintaining market value of listed securities at or above $50 million for at least 10 consecutive business days; failure could lead to delisting proceedings.
-
Liquidity and capital-raising impact
If delisted and not accepted for Nasdaq Capital Market listing, the company expects trading could move to an over-the-counter market, and its securities could become subject to SEC penny-stock rules; continued listing also includes a $1.00 minimum bid-price standard.
Management's outlook
No quantitative revenue or EPS outlook is provided in the extracted filing text; outlook appears deferred to other company communications.
Earlier filings 4
10-K · March 26, 2026
Actuate Therapeutics reports positive Phase 2 results in first-line metastatic pancreatic cancer (Actuate-1801 Part 3B) showing statistically significant survival benefit versus GnP and plans regulatory discussions in…
10-Q · May 15, 2025
Actuate reported a Q1 2025 net loss of $6,317,024 (loss per share $(0.32)) and used $4,618,740 in operating cash during the quarter. Cash declined to $3,889,405 from $8,641,622 at year-end, management says cash will not…
10-Q · September 24, 2024
Actuate reported no revenue and a larger net loss for Q2 2024: net loss was $(6,572,219) and diluted EPS was $(4.20) versus $(5,524,286) and $(3.88) in Q2 2023. Liquidity was stressed at June 30, 2024 with cash of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.